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Based on pedigree data and haplotype sharing, a common 
ancestor should be situated more than 7 generations ago. 
RT-PCR demonstrated the presence of aberrant messenger 
RNA. Clinical manifestations ranged from severe disease to 
nonpenetrance in elderly mutation carriers.  Conclusions: 
This founder mutation in  PKP2 is predicted to lead to the 
presence of a dysfunctional PKP2 protein, whereas most 
truncating mutations are expected to lead to loss of protein. 
Mutation carriers displayed a wide range of disease severity, 
suggesting that  PKP2 mutations alone are not sufficient to 
cause disease, which results in the variable expression and 
incomplete penetrance characteristic of ARVD/C mutations. 
 Copyright © 2012 S. Karger AG, Basel 
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 Objectives: Arrhythmogenic right ventricular dysplasia/car-
diomyopathy (ARVD/C) is characterized by fibrofatty re-
placement of cardiomyocytes. In around 50% of index pa-
tients, a genetic predisposition is demonstrated. The pur-
pose of this study was to examine a plakophilin-2  (PKP2) 
splice site mutation, c.2489+4A 1 C, identified in 4 separately 
ascertained Dutch ARVD/C families.  Methods: Genealogical 
studies and comprehensive screening of 5 desmosomal 
genes were undertaken. Reverse transcriptase PCR (RT-PCR) 
and subsequent sequencing was performed.  Results: An A-
to-C change (c.2489+4A 1 C) near the splice donor site of in-
tervening sequence 12 of  PKP2 was found in all 4 families. 
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 Introduction 
 Arrhythmogenic right ventricular dysplasia/cardio-
myopathy (ARVD/C) is a disorder characterized by pro-
gressive replacement of cardiomyocytes by fibrofatty tis-
sue, primarily in the right ventricle. Life-threatening ven-
tricular arrhythmias originating from the right ventricle 
can be an early manifestation of the disease. Clinical di-
agnosis depends on the fulfillment of Task Force Criteria 
(TFC)  [1] , for which modifications have recently been 
proposed  [2] .
 An important genetic contribution is evident from the 
fact that in 30–50% of cases one or more first-degree rel-
atives also display signs of the disease  [3, 4] . A large ma-
jority of mutations in ARVD/C patients has been found 
in genes encoding different components of the cardiac 
desmosome, i.e. plakophilin-2  (PKP2) , desmocollin-2 
 (DSC2) , desmoglein-2  (DSG2) , desmoplakin  (DSP) , and 
plakoglobin  (JUP)  [5–12] , suggesting that ARVD/C is pri-
marily a disease of disturbed desmosomal function  [13, 
14] . Mutations in other genes have also been reported in 
ARVD/C, i.e. among others, transmembrane protein 43 
 (TMEM43) , desmin  (DES) , and titin  (TTN)  [15–18] , indi-
cating genetic heterogeneity. In addition, several ARVD/C 
cases were found to be caused by multiple mutations in 
the same gene (compound heterozygosity) or mutations 
in different genes (digenic inheritance), which could re-
sult in an earlier onset and increased disease severity  [19–
21] . The precise mechanisms by which mutations in these 
genes lead to the distinct ARVD/C phenotype remain, to 
a large extent, to be elucidated. Decreased desmosome 
numbers, structurally abnormal desmosomes, secondary 
effects on other intercalated disk structures, or impaired 
Wnt/beta-catenin signaling, resulting in increased ex-
pression of adipogenic and fibrogenic genes and fat ac-
cumulation, may all contribute to the ARVD/C patho-
physiology  [22–24] . However, regardless of the gene that 
is mutated, translocation of plakoglobin from the desmo-
some to the cytosol may be an important common step 
in disease causation  [22, 24, 25] .
 It has been shown that mutations in  PKP2 are frequent 
in ARVD/C patients in the northwestern part of Europe 
and the USA  [5, 7, 26, 27] . In a cohort of Dutch ARVD/C 
patients up to 90% of  PKP2 mutations were found in cas-
es of proven familial disease  [21] . Eight different recur-
rent  PKP2  mutations have been found in the Dutch pop-
ulation, accounting for 84% (41/49) of separately ascer-
tained  PKP2- positive ARVD/C families. For some of 
them a shared  PKP2  haplotype was demonstrated, while 
other families could be traced back to a common ancestor 
by genealogy, sometimes as far as 10 generations ago  [7] . 
Therefore, it is likely that several different  PKP2  founder 
mutations segregate in The Netherlands, which may con-
tribute to the high prevalence of  PKP2  mutations in Dutch 
ARVD/C patients.
 Looking at the spectrum of different mutations report-
ed in  PKP2 , it is evident that truncating mutations (non-
sense and frameshift) are most frequent  [28] . The classifi-
cation of missense variants as pathogenic, in  PKP2  as well 
as in other genes, remains challenging without solid func-
tional evidence  [29] . Truncating mutations are predicted 
to lead to loss of PKP2 protein by nonsense-mediated mes-
senger RNA decay (NMD), although mRNA studies by 
Gerull et al.  [5] showed that the identified splice mutations 
had detectable mRNA with frameshifts, resulting in pre-
mature termination codons, that may evade NMD. As a 
general rule, introduction of a stop codon more than 50–
55 nucleotides upstream of the last exon-intron bound-
ary of any gene will lead to the breakdown of messenger-
RNA in vivo, resulting in only very little translation of the 
abnormal truncated protein  [30] . This is an argument for 
haploinsufficiency (insufficient amounts of normal PKP2) 
as the predominant mechanism by which  PKP2 muta-
tions predispose to disease, as opposed to a dominant
negative effect due to the presence of abnormal PKP2
protein. Indeed, a Western blot from a heart biopsy
from a patient with  PKP2  mutation c.2076_2077delAA 
(p.Ser693CysfsX49) did not show detectable protein  [5] .
 This report discusses both the clinical characteristics 
of patients from 4 different families that were found to 
have an identical splice mutation (c.2489+4A 1 C) at the 
C-terminal end of the  PKP2  gene, and the possible mech-
anism by which it exerts its effect.
 Methods 
 Clinical Evaluation 
 All index patients and their relatives were evaluated at the
Cardiology Departments of the University Medical Centers in 
Utrecht and Amsterdam. Family members were evaluated follow-
ing a genetic counseling procedure and after informed consent 
had been obtained. The evaluation consisted of at least a physical 
examination, 12-lead ECG, and echocardiography. Diagnosis was 
based on the recently modified ARVD/C TFC  [2] .
 Genealogy 
 Since 1997, genealogical studies have been performed in new-
ly ascertained ARVD/C cases, in order to select patients that could 
contribute to the finding of new ARVD/C loci, using identity by 
descent strategies  [31] . Investigations were carried out using com-
munity registries, starting from information on the grandparents 
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 Molecular Genetic Analyses 
 DNA was isolated from peripheral lymphocytes according to 
standard protocols. In index patients the coding regions of the 
 PKP2 , DSC2 , DSG2 , DSP ,  JUP,  and  TMEM43 genes were analyzed 
using denaturing high-performance liquid chromatography 
( PKP2 ,  DSC2 , and  DSG2 ) as described previously  [32] , and/or di-
rect sequencing ( DSP ,  JUP , and  TMEM43 ). Direct sequencing was 
performed with a BigDye Terminator DNA sequencing kit (ver-
sion 2.0) on a 3730 automated sequencer (Applied Biosystems, 
Foster City, Calif., USA). All sequences were analyzed using
SeqScape software (version 2.1.1, Applied Biosystems). In addi-
tion, multiplex ligation-dependent probe amplification analysis 
was performed to exclude large deletions in  PKP2 (SALSA multi-
plex ligation-dependent probe amplification kit P168 ARVC-
PKP2; MRC Holland, Amsterdam, The Netherlands). Relatives of 
index patients were only analyzed for the presence of a previously 
identified mutation.
 Total RNA was isolated from fresh blood samples from in-
dividual VII:6 and a control individual using a PAXgene kit
(QIAGEN Benelux, Venlo, The Netherlands) and subjected to 
random hexamer primed reverse transcriptase PCR (RT-PCR). 
The obtained cDNA products were amplified by PCR with prim-
ers specific for the  PKP2  coding sequence.  PKP2 cDNA fragments 
were separated according to size using 2% agarose gel electropho-
resis along with a 100-bp DNA ladder (O’GeneRuler; Fermentas, 
Burlington, Ont., Canada). Both normal and aberrant fragments 
were gel purified and used for direct sequencing. Primers and 
PCR details are available upon request.
 Results 
 Genealogy 
 In families 2 and 3 ( fig.  1 ), common ancestors were 
found who were born around 1780 AD. Family 1 could be 
linked to family 2, but a link with the common ancestors 
in families 2 and 3 could not be established. Family 4 
could not be traced back to the same ancestors, yet all an-
cestors lived in the same region.
 Fig. 1. Pedigrees of families 1–4. Squares denote males, circles fe-
males. Black squares/circles denote individuals that satisfy the 
2010 TFC for a clinical diagnosis of ARVD/C ( 6 4 points). Upper 
right quadrant-blackened squares/circles denote individuals that 
did not fulfill the TFC but did have abnormalities compatible with 
ARVD/C at their most recent cardiac examination. +/– indicates 
the presence or absence of the  PKP2  c.2489+4A 1 C mutation. In-
dividuals denoted with ‘n’ had a normal cardiac evaluation. Num-
bers in squares/circles denote the number of individuals.  *  Geno-



















   
   
   
   
   
   
   
   
   



















 van der Smagt et al. Cardiology 2012;123:181–189184
 Molecular Genetic Analyses 
 Analysis of the entire coding regions of  PKP2, DSC2, 
DSG2, DSP,  JUP, and  TMEM43 including exon-intron 
boundaries in the 4 index patients revealed a c.2489+
4A 1 C mutation in the  PKP2  gene. Besides this interven-
ing sequence mutation, no other mutations, including 
large deletions in  PKP2 , were found. The  PKP2 
 c.2489+4A 1 C mutation is within the splice donor con-
sensus sequence. Splice prediction programs were incon-
clusive with respect to a predicted effect on splicing ( ta-
ble  1 ). The mutation was absent in over 150 ethnically 
matched controls (300 alleles) and not annotated in both 
dbSNP and the 1000 Genomes Project databases (ac-
cessed October 10, 2011). In addition to the 4 index pa-
tients, 10 relatives were also found to carry the  PKP2 
 c.2489+4A 1 C mutation.
 RT-PCR demonstrated the presence of an abnormal 
 PKP2 messenger RNA ( fig. 2 a), indicating that the effect 
of the c.2489+4A 1 C mutation is indeed through aber-
rant splicing. The abnormal  PKP2  messenger RNA lacks 
the entire exon 12 (190 bp) ( fig. 2 b). In the predicted pro-
tein a frameshift occurs that leads to stop codon 99 resi-
dues downstream, well within the 3  untranslated region 
of the  PKP2 gene. Therefore, all residues normally en-
coded by exons 12, 13, and 14 are missing from the abnor-
mal transcript, but the predicted abnormal protein is only 
Table 1.  Results of splice prediction programs
Splice prediction program Wild type c.2489+4A>C
mutation
Notes
NetGene2 0.93 0.91 both ‘highly confident donor sites’
NNSPLICE 0.9 0.98 0.57 donor score cutoff: 0.40




R esults of the different prediction programs for the normal exon 12 donor splice site are shown. Splice pre-
dictions are available from the following websites: NetGene2: www.cbs.dtu.dk/services/NetGene2, NNSPLICE 
0.9: www.fruitfly.org/seq_tools/splice.html, MaxEntScan: genes.mit.edu/burgelab/maxent/Xmaxentscan_
scoreseq.html, GeneSplicer: www.cbcb.umd.edu/software/GeneSplicer, and Alamut: www.interactive-biosoft-
ware.com.
a b
 Fig. 2. RT-PCR for the  PKP2  c.2489+4A 1 C mutation.  a Two per-
cent agarose gel electrophoresis showing cDNA products derived 
from mRNA of a control sample and index patient VII:6. The first 
lane shows a 100-bp ladder, followed by the control, the patient 
sample, and a blank with primers in exons 11 and 13. The expect-
ed normal cDNA product with primers in exons 11 and 13 is 335 
bp in length. The shorter transcript in the patient sample (lane 3) 
lacks exon 12 (190 bp) as shown in b. The bands in the patient 
sample show an   1: 1 ratio, indicating that preferred PCR of the 
shorter transcript, lacking exon 12, did not occur. This could in-
dicate partial degradation of the mutated mRNA.  b Sequencing 
of the cDNA derived from both the normally spliced transcript 
and the abnormally spliced transcript demonstrating the skip-
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15 residues shorter than the wild-type protein ( fig.  3 ). 
Since the stop codon occurs in the 3  untranslated region, 
the abnormal protein cannot be subjected to NMD.
 Clinical Evaluation 
 All index patients with the  PKP2  c.2489+4A 1 C muta-
tion fulfilled the modified TFC for ARVD/C  [2] .  Figure 1 
shows the pedigree of all families, and clinical data on the 
 PKP2  c.2489+4A 1 C mutation carriers are summarized 
in  table 2 . Index patient 1 (VI:1) was admitted to the hos-
pital at the age of 33 years with sustained monomorphic 
ventricular tachycardia (VT) (240/min) with left bundle 
branch block (LBBB) morphology during exercise. He ex-
perienced at least 4 other episodes of VT, but no syncope. 
Supraventricular tachycardias also occurred, caused by 
AV nodal re-entry and provoked by premature ventricu-
lar complexes. Radiofrequency (RF) ablation was per-
formed for the ventricular arrhythmias from the right 
ventricular outflow tract and for the AV nodal re-entry 
tachycardia (AVNRT). He has been doing well on diso-
pyramide medication for 12 years. Index patient 2 (VI:5) 
has been known to have frequent VT episodes with LBBB 
morphology since the age of 20, which were treated with 
RF ablation. At the age of 36 she had an out-of-hospital 
cardiac arrest (OHCA) due to ventricular fibrillation 
(VF) while on sotalol. Subsequently an implantable car-
dioverter defibrillator (ICD) was implanted, which has 
delivered appropriate anti-tachycardia pacing and shocks. 
Index patient 3 (VII:6) experienced syncope at the age of 
26 during exercise. She was admitted with a wide QRS 
complex tachycardia (250/min). Treatment with diso-
pyramide was started. An AVNRT was diagnosed at elec-
trophysiological study, which was treated with RF abla-
tion, after a second arrhythmia episode. She has been free 
of symptoms for 14 years. Index patient 4 (VI:10) had an 
OHCA with VF at the age of 29. He received an ICD and 
was treated with metoprolol for VTs. At the age of 33 he 
experienced two episodes with electrical storms possibly 
triggered by a viral infection. Metoprolol was changed to 
sotalol and amiodarone was added. The patient has been 
doing well for 9 years.
 In addition to the 4 index patients, 2 of the mutation-
positive family members developed clinical complaints 
likely related to ARVD/C, resulting in 6 symptomatic 
mutation carriers. In family 4, a 34-year-old male (VI:9), 
who had had no complaints at the initial evaluation, re-
ceived an ICD after he suffered a near syncope while al-
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 Fig. 3. Aberrant splicing as a result of the  PKP2  c.2489+4A 1 C 
mutation. A and B represent the C-terminus of the normal pla-
kophilin-2 protein and the normally spliced mRNA, respectively. 
C depicts part of the genomic DNA of the PKP2 gene [exons in 
white, introns (IVS) in grey, 3  untranslated region (UTR) in 
black] with the position of the wild-type splice site above the bar 
and the mutated splice site below the bar. D and E show the aber-
rant splice product and the predicted abnormal protein, respec-
tively. The abnormal protein is only 15 amino acid residues short-
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insufficient duration to warrant ICD therapy were subse-
quently recorded. His sister (VI:8) received an ICD short-
ly after she experienced a near syncope during a stressful 
event. Although without any signs of disease at initial 
evaluation at the age of 33, she developed aneurysmatic 
changes of the right ventricle in the course of 9 years.
 Remarkably, 7 of the 13 mutation carriers (age range 
at first evaluation 15–69 years) who were evaluated were 
asymptomatic. In 4 of them only a major criterion for a 
positive family history was available, leading to a possible 
clinical status according to the modified TFC. In 3 of the 
asymptomatic carriers additional criteria were present, 
resulting in a borderline diagnosis in 1 and a definite di-
agnosis in 2 asymptomatic carriers  [2] .
 Left ventricular (LV) involvement was not systemati-
cally assessed in these families. Cardiac MRI was per-
formed in 5 mutation carriers; all of them showed normal 
LV volumes and LV ejection fraction. None of them 
showed LV wall motion abnormalities or late gadolinium 
enhancement. Index patient VI:5 experienced VT with 
RBBB morphology, but she had a normal LV function. 
Finally, none of the mutation carriers had isolated invert-
ed T-waves in the left precordial leads V4–V6.
 Discussion 
 PKP2 mutations are a frequent cause of ARVD/C. The 
 PKP2 gene was first implicated in ARVD/C through a 
candidate gene approach  [5] . The fact that the  PKP2 locus 
had not been previously found in linkage studies can be 
explained by low penetrance resulting in phenotype-neg-
ative family members who were classified as unaffected, 
although they were in fact mutation carriers. Previously, 
the haplotype sharing test identified a shared haplotype 
on chromosome 12p12.1–12q13.13, encompassing  PKP2, 


































V:2 F 61 0 none ++ 2 Pos none no follow-up




VI:3 F 35 7 none + ++ 3 Bor none no progression
Family 2
VI:5 F 20 20 32 VT/VF/
OHCA




VII:3 M 17 11 none ++ + ++ 5 Aff none mild progression
VII:4 F 15 11 none ++ 2 Pos none no progression
V:7 F not evaluated
Family 3
VII:6d F 26 26 14 syncope + ++ + ++ ++ 8 Aff RF ablation concurrent AVNRT,
no progression
VI:7 F 62 3 none ++ 2 Pos none no progression
Family 4
VI:10 M 29 29 9 VF/
OHCA




V:11 F 59 9 none ++ 2 Pos none mild progression
VI:8 F 40 33 9 near
syncope
++ ++ 4 Aff ICD evident progression
VI:9 M 34 32 9 near
syncope
++ ++ 4 Aff ICD, sotalol mild progression
AF  = Atrial fibrillation; Aff = affected; Bor = borderline; F = female; ICD~ = ICD 
discharge; LV = left ventricle; M = male; NA = not available; nsVT = nonsustained ven-
tricular tachycardia; Pos = possibly; RV = right ventricle; sVT = sustained ventricular 
tachycardia.
a Not available. b Minor criteria yield 1 point and major criteria 2 points; for a defi-
nite diagnosis of ARVD/C a minimum of 4 points is required, 3 points indicate a bor-
derline diagnosis, and 2 points indicate a possible diagnosis. c For this patient a biopsy 
was available; it showed fibrosis but no fat and was considered inconclusive. d Syncope 
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as the largest shared haplotype in these families  [33] . The 
haplotype sharing test compares the genotypes from SNP 
arrays, using an affected-only strategy, to search for large 
shared haplotypes within pedigrees most likely to con-
tain a causative mutation. In these families, the haplotype 
sharing test indicated a common founder, who must have 
lived well before the 19th century. Based on pedigree 
data, it was estimated that the most recent common an-
cestor should be situated over 7 generations ago. How-
ever, these are crude estimations since only 4 families 
were available. The actual age of the mutation could be 
considerably older. Little is known about the age of  PKP2 
mutations. Our data show that mutations may have oc-
curred many generations earlier, in the absence of a fam-
ily history of cardiac disease. The fact that in some fami-
lies we have been able to demonstrate common ancestors 
as far as 10 generations back by genealogy suggests that 
reproductive fitness in ARVD/C is not significantly re-
duced.
 The  PKP2  c.2489+4A 1 C mutation seems to be rela-
tively frequent in The Netherlands, having been detected 
in 4 independently ascertained ARVD/C families so far. 
Another 5 mutations (c.235C 1 T, c.397C 1 T, c.1211–
1212dupT, c.2386T 1 C, and c.2489+1G 1 A) in  PKP2 oc-
curred at least as frequently in the Dutch ARVD/C co-
hort. Haplotype analysis and genealogy suggest that there 
may also be common founders contributing to these mu-
tations, explaining the high prevalence of  PKP2 muta-
tions in Dutch ARVD/C patients  [32, 34] .
 The frequent occurrence of nonsense and frameshift 
mutations in  PKP2 is indicative that the causative mech-
anism at the protein level is that of loss of normal  PKP2 
function, as most of these mutations are predicted to lead 
to NMD  [28] . Gerull et al.  [5] , while performing Western 
blot analysis on cardiac tissue in a patient with a  PKP2 
 c. 2 076_2077delAA mutation, demonstrated reduced 
wild-type PKP2 but were unable to demonstrate the pre-
dicted abnormal protein. This is in keeping with the con-
cept of NMD in the heart. As the  PKP2  c.2489+4A 1 C 
mutation cannot be subjected to NMD, it is predicted to 
lead to a dysfunctional  PKP2 protein. However, we can-
not exclude degradation of the abnormal protein through 
other mechanisms, which could still lead to haploinsufi-
ciency. If a dysfunctional protein is present, the last two 
conserved armadillo repeat regions would be disrupted, 
completely altering the C-terminal tail. The exact role of 
the C-terminal tail is unknown, while the N-terminal 
part of the protein is most important for binding other 
desmosomal proteins and targeting PKP2 to the plasma 
membrane  [35] . The pathogenic effect of splice mutations 
may be ameliorated when the induced aberrant splicing 
is not absolute, as has been shown for the only recessive 
 PKP2 mutation thus far  [36] . In the absence of heterozy-
gous polymorphisms in exons 12–14 of the  PKP2  gene, 
the presence of a normal transcript from the diseased al-
lele could not be assessed.
 In total 14 patients with the  PKP2  c.2489+4A 1 C mu-
tation (4 males, 10 females), including index patients, 
were identified in the 4 families. Despite the overrepre-
sentation of female mutation carriers in this study, 2 out 
of 4 index patients were males. Nine out of 10 family 
members with a mutation had a cardiac workup. Only 2 
of 9 evaluated mutation-positive family members devel-
oped clinical complaints ( table 2 ). Five family members 
fulfilled the modified TFC for ARVD/C. Incomplete pen-
etrance and clinical variability are characteristic for 
ARVD/C  [4] and were also seen in the families with the 
 PKP2  c.2489+4A 1 C mutation. Compound heterozygos-
ity or digenic inheritance for mutations in the desmo-
somal genes or in  TMEM43 had been excluded as an ex-
planation for this variability, but other genetic, epigene-
tic, or nongenetic factors, such as lifestyle, could have 
contributed to the clinical differences observed in these 
families.
 Which preventive treatment modalities are justified in 
asymptomatic  PKP2 mutation carriers is currently unde-
termined. We suggest that they be followed-up regularly 
in order to assess disease progression with annual echo-
cardiography, Holter monitoring, and exercise testing. 
Besides, additional cardiac MRI at intervals no longer 
than 5 years (or before implantation of an ICD) is deemed 
appropriate in The Netherlands.
 Although we find molecular diagnosis in ARVD/C to 
be a useful tool in identifying persons at risk for develop-
ing ARVD/C, its value is still limited by the inability to 
accurately predict phenotypes from genotypes, especially 
when a missense variant is identified  [29] . The fact that 
many identified  PKP2 mutation carriers will never expe-
rience life-threatening arrhythmias emphasizes the need 
for identifying the truly pathogenic mutations as well as 
other genetic or environmental factors that play a role in 
disease causation. We believe that the described  PKP2 
 c.2489+4A 1 C mutation is pathogenic, based on its co-
segregation with the ARVD/C phenotype, the absence of 
the mutation in controls as well as in the dbSNP, and the 
1000 Genomes Project databases, the fact that the muta-
tion is located on the largest shared haplotype, indicating 
a founder effect  [33] , and the RT-PCR which demonstrat-
ed the presence of an abnormal  PKP2 messenger RNA 
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tions implicated in ARVD/C, the c.2489+4A 1 C muta-
tion is characterized by incomplete penetrance, indicat-
ing that not all mutation carriers will develop the disease. 
The mutation is predicted to lead to the presence of a dys-
functional PKP2 protein, whereas most truncating muta-
tions are expected to lead to loss of protein. Mutation car-
riers displayed a wide range of disease severity, suggest-
ing that  PKP2 mutations alone are not sufficient to cause 
disease.
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